Clinical experience of immune checkpoint inhibitor for a metastatic jejunal cancer patient with a high tumor mutational burden and low expression of programmed death-ligand 1

Recent data showed that DNA mismatch repair deficiency can be a predictive biomarker for a favorable response of immune checkpoint inhibitors regardless of tumor type due to give rise to high tumor mutational burden (TMB) and microsatellite instability (MSI). Loss-of-function mutations of a specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seo Ree, Chun, Sang Hoon, Kim, Ji Hyun, Kim, Sang-Yeob, Lee, Bo-In, Jung, Chan Kwon, Kang, Jin Hyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Surgical Oncology 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942715/
https://www.ncbi.nlm.nih.gov/pubmed/36945301
http://dx.doi.org/10.14216/kjco.20010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942715/
https://www.ncbi.nlm.nih.gov/pubmed/36945301
http://dx.doi.org/10.14216/kjco.20010

Ejemplares similares